![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Publisher: Adis International
ISSN: 1173-8324
Source: Inpharma, Vol.1, Iss.1515, 2005-01, pp. : 4-4
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
UK NICE issues guidance on infliximab in Crohn's disease
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 363, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Scheduled infliximab maintenance worthy for Crohn's disease in UK
Inpharma, Vol. 1, Iss. 1650, 2008-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
UK NICE issues guidance on infliximab in Crohn's disease
Inpharma, Vol. 1, Iss. 1338, 2002-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab promising in paediatric Crohn's disease
Inpharma, Vol. 1, Iss. 1391, 2003-01 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Infliximab: additional benefits in Crohn's disease
Inpharma, Vol. 1, Iss. 1349, 2002-01 ,pp. :